HYDROCHLOROTHIAZIDE; VALSARTAN | A078946 | LUPIN LTD
No patent or exclusivity listings for this strength.
Lupin Ltd's valsartan and hydrochlorothiazide product (NDA 078946, supplement 005) therapeutic equivalence rating changed from AB to a different code.
Old: AB
Lupin Ltd's valsartan and hydrochlorothiazide product (NDA 078946, strength 002) transitioned from prescription to discontinued status.
Old: RX
New: DISCN
Lupin Ltd's valsartan and hydrochlorothiazide product (NDA 078946, strength 003) therapeutic equivalence code changed from AB to a different rating.
Old: AB
Lupin Ltd's valsartan and hydrochlorothiazide product (NDA 078946, strength 004) had its therapeutic equivalence code changed from AB to a different rating.
Old: AB
Lupin Ltd's Valsartan and Hydrochlorothiazide product (NDA 078946) transitioned from prescription to discontinued status.
Old: RX
New: DISCN
Lupin's valsartan and hydrochlorothiazide combination (NDA 078946) therapeutic equivalence code changed from AB to a different rating.
Old: AB
Lupin Ltd's valsartan and hydrochlorothiazide combination product (NDA 078946, supplement 005) transitioned from prescription to discontinued status.
Old: RX
New: DISCN
Lupin Ltd's Valsartan and Hydrochlorothiazide (NDA 078946, strength 002) therapeutic equivalence code changed from AB, affecting generic substitutability classification.
Old: AB
Lupin Ltd's valsartan and hydrochlorothiazide product (NDA 078946, strength 003) transitioned from prescription to discontinued status.
Old: RX
New: DISCN
Lupin Ltd's valsartan and hydrochlorothiazide product (NDA 078946) transitioned from prescription to discontinued status.
Old: RX
New: DISCN